The results support the fact that the immune response in early breast cancer is mediated, among other, by cells that secrete IL-17A, and that after the removal of the tumor, even though the reaction mediated by IL-17A subsides, serum IL-17A level remains elevated compared to the healthy population. The gene discussed is IL17A; the disease is neoplasm.